Abstract
There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.
MeSH terms
-
Antiviral Agents / adverse effects*
-
Drug Therapy, Combination
-
Female
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Liver Function Tests
-
Middle Aged
-
Polyethylene Glycols / adverse effects*
-
Recombinant Proteins
-
Ribavirin / adverse effects*
-
Skin / drug effects
-
Vasculitis / chemically induced*
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a